FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study.
Publication
, Conference
Secord, AA; Barroilhet, LM; Lim, MC; Gupta, S; Oosman, S; Rao, JS; Schorge, JO; Barlin, JN; Gilbert, L; Tewari, D; Gold, M; Provencher, DM ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Barroilhet, L. M., Lim, M. C., Gupta, S., Oosman, S., Rao, J. S., … O’Malley, D. M. (2022). FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Secord, Angeles Alvarez, Lisa Marie Barroilhet, Myong Cheol Lim, Sunil Gupta, Sonia Oosman, Jada Srinivas Rao, John O. Schorge, et al. “FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Secord AA, Barroilhet LM, Lim MC, Gupta S, Oosman S, Rao JS, et al. FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Secord, Angeles Alvarez, et al. “FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Secord AA, Barroilhet LM, Lim MC, Gupta S, Oosman S, Rao JS, Schorge JO, Barlin JN, Gilbert L, Tewari D, Gold M, Provencher DM, Lee J-Y, Bixel KL, Yanez E, Rob L, O’Malley DM. FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double-blind, placebo-controlled, global, multinational study. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences